Movement disorders after hypoxic brain injury following cardiac arrest in adults.
cardiac arrest
hypoxic-ischaemic encephalopathy
intrathecal baclofen
levomepromazine
myoclonus
post-hypoxic movement disorder
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
03
03
2020
accepted:
07
05
2020
pubmed:
18
5
2020
medline:
7
7
2021
entrez:
17
5
2020
Statut:
ppublish
Résumé
Post-hypoxic movement disorders and chronic post-hypoxic myoclonus are rare complications after cardiac arrest in adults. Our study investigates the clinical spectrum, neuroimaging results, therapy and prognosis of these debilitating post-hypoxic sequelae. This retrospective study included 72 patients from the neurological intensive care unit at a university hospital, who were diagnosed with hypoxic-ischaemic encephalopathy after cardiac arrest between January 2007 and September 2018. Clinical records were screened for occurrence of post-hypoxic movement disorders and chronic post-hypoxic myoclonus. Affected patients were further analysed for applied neuroprognostic tests, administered therapy and treatment response, and the outcome of these movement disorders and neurological function. Nineteen out of 72 screened patients exhibited post-hypoxic motor symptoms. Basal ganglia injury was the most likely neuroanatomical correlate of movement disorders as indicated by T1 hyperintensities and hypometabolism of this region in magnetic resonance imaging and positron emission tomography computed tomography. Levomepromazine and intrathecal baclofen showed first promising and mostly prompt responses to control these post-hypoxic movement disorders and even hyperkinetic storms. In contrast, chronic post-hypoxic myoclonus best responded to co-application of clonazepam, levetiracetam and primidone. Remission rates of post-hypoxic movement disorders and chronic post-hypoxic myoclonus were 58% and 50%, respectively. Affected patients seemed to present a rather good recovery of cognitive functions in contrast to the often more severe physical deficits. Post-hypoxic movement disorders associated with pronounced basal ganglia dysfunction might be efficiently controlled by levomepromazine or intrathecal baclofen. Their occurrence might be an indicator for a more unfavourable, but often not devastating, neurological outcome.
Sections du résumé
BACKGROUND AND PURPOSE
Post-hypoxic movement disorders and chronic post-hypoxic myoclonus are rare complications after cardiac arrest in adults. Our study investigates the clinical spectrum, neuroimaging results, therapy and prognosis of these debilitating post-hypoxic sequelae.
METHODS
This retrospective study included 72 patients from the neurological intensive care unit at a university hospital, who were diagnosed with hypoxic-ischaemic encephalopathy after cardiac arrest between January 2007 and September 2018. Clinical records were screened for occurrence of post-hypoxic movement disorders and chronic post-hypoxic myoclonus. Affected patients were further analysed for applied neuroprognostic tests, administered therapy and treatment response, and the outcome of these movement disorders and neurological function.
RESULTS
Nineteen out of 72 screened patients exhibited post-hypoxic motor symptoms. Basal ganglia injury was the most likely neuroanatomical correlate of movement disorders as indicated by T1 hyperintensities and hypometabolism of this region in magnetic resonance imaging and positron emission tomography computed tomography. Levomepromazine and intrathecal baclofen showed first promising and mostly prompt responses to control these post-hypoxic movement disorders and even hyperkinetic storms. In contrast, chronic post-hypoxic myoclonus best responded to co-application of clonazepam, levetiracetam and primidone. Remission rates of post-hypoxic movement disorders and chronic post-hypoxic myoclonus were 58% and 50%, respectively. Affected patients seemed to present a rather good recovery of cognitive functions in contrast to the often more severe physical deficits.
CONCLUSIONS
Post-hypoxic movement disorders associated with pronounced basal ganglia dysfunction might be efficiently controlled by levomepromazine or intrathecal baclofen. Their occurrence might be an indicator for a more unfavourable, but often not devastating, neurological outcome.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1937-1947Subventions
Organisme : H2020 Research and Innovation Action grants VirtualBrainCloud
ID : 826421
Pays : International
Organisme : Human Brain Project
ID : 650003, 785907 and ERC 683049
Pays : International
Organisme : German Research Foundation
ID : CRC 1315, grant RI 2073/6-1
Pays : International
Organisme : NeuroCure Excellence Cluster
ID : EXC 257
Pays : International
Informations de copyright
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Girotra S, Nallamothu BK, Spertus JA, et al. Trends in survival after in-hospital cardiac arrest. N Engl J Med 2012; 367: 1912-1920.
Lu-Emerson C, Khot S. Neurological sequelae of hypoxic-ischemic brain injury. NeuroRehabilitation 2010; 26: 35-45.
van Zijl JC, Beudel M, vd Hoeven HJ, Lange F, Tijssen MAJ, Elting JWJ. Electroencephalographic findings in posthypoxic myoclonus. J Intensive Care Med 2016; 31: 270-275.
Manji H, Howard RS, Miller DH, et al. Status dystonicus: the syndrome and its management. Brain 1998; 121: 243-252.
English WA, Giffin NJ, Nolan JP. Myoclonus after cardiac arrest: pitfalls in diagnosis and prognosis. Anaesthesia 2009; 64: 908-911.
Venkatesan A, Frucht S. Movement disorders after resuscitation from cardiac arrest. Neurol Clin 2006; 24: 123-132.
Marsden CD, Marion MH, Quinn N. The treatment of severe dystonia in children and adults. J Neurol Neurosurg Psychiatry 1984; 47: 1166-1173.
Fehlings D, Brown L, Harvey A, et al. Pharmacological and neurosurgical interventions for managing dystonia in cerebral palsy: a systematic review. Dev Med Child Neurol 2018; 60: 356-366.
Krauss GL, Bergin A, Kramer RE, Cho YW, Reich SG. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 2001; 56: 411-412.
Scheel M, Storm C, Gentsch A, et al. The prognostic value of gray-white-matter ratio in cardiac arrest patients treated with hypothermia. Scand J Trauma Resusc Emerg Med 2013; 21: 23.
Lange C, Suppa P, Frings L, Brenner W, Spies L, Buchert R. Optimization of statistical single subject analysis of brain FDG PET for the prognosis of mild cognitive impairment-to-Alzheimer's disease conversion. J Alzheimers Dis 2016; 49: 945-959.
Yushkevich PA, Piven J, Hazlett HC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. NeuroImage 2006; 31: 1116-1128.
Horn A, Li N, Dembek TA, et al. Lead-DBS v2: towards a comprehensive pipeline for deep brain stimulation imaging. NeuroImage 2019; 184: 293-316.
Petzinka VN, Endisch C, Streitberger KJ, et al. Unresponsive wakefulness or coma after cardiac arrest - a long-term follow-up study. Resuscitation 2018; 131: 121-127.
Monbaliu E, Himmelmann K, Lin JP, et al. Clinical presentation and management of dyskinetic cerebral palsy. Lancet Neurol 2017; 16: 741-749.
Scott BL, Jankovic J. Delayed-onset progressive movement disorders after static brain lesions. Neurology 1996; 46: 68-74.
Quartarone A, Hallett M. Emerging concepts in the physiological basis of dystonia. Mov Disord 2013; 28: 958-967.
Kojovic M, Parees I, Kassavetis P, et al. Secondary and primary dystonia: pathophysiological differences. Brain 2013; 136: 2038-2049.
Bhatt MH, Obeso JA, Marsden CD. Time course of postanoxic akinetic-rigid and dystonic syndromes. Neurology 1993; 43: 314-317.
Green B, Pettit T, Faith L, Seaton K. Focus on levomepromazine. Curr Med Res Opin 2004; 20: 1877-1881.
Lal S, Nair NP, Cecyre D, Quirion R. Levomepromazine receptor binding profile in human brain - implications for treatment-resistant schizophrenia. Acta Psychiatr Scand 1993; 87: 380-383.
Albright AL. Intrathecal baclofen in cerebral palsy movement disorders. J Child Neurol 1996; 11: S29-S35.
Kuoppamaki M, Bhatia KP, Quinn N. Progressive delayed-onset dystonia after cerebral anoxic insult in adults. Mov Disord 2002; 17: 1345-1349.
Seder DB, Sunde K, Rubertsson S, et al. Neurologic outcomes and postresuscitation care of patients with myoclonus following cardiac arrest. Crit Care Med 2015; 43: 965-972.
Sandroni C, D'Arrigo S, Nolan JP. Prognostication after cardiac arrest. Crit Care 2018; 22: 150.
Ruijter BJ, Tjepkema-Cloostermans MC, Tromp SC, et al. Early electroencephalography for outcome prediction of postanoxic coma: a prospective cohort study. Ann Neurol 2019; 86: 203-214.
Wijdicks EF, Parisi JE, Sharbrough FW. Prognostic value of myoclonus status in comatose survivors of cardiac arrest. Ann Neurol 1994; 35: 239-243.
van Zijl JC, Beudel M, Elting JJ, et al. The inter-rater variability of clinical assessment in post-anoxic myoclonus. Tremor Other Hyperkinet Mov 2017; 7: 470.
Mikhaeil-Demo Y, Gavvala JR, Bellinski II, et al. Clinical classification of post anoxic myoclonic status. Resuscitation 2017; 119: 76-80.
Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 1985; 35: 73-77.
Ewert S, Horn A, Finkel F, Li N, Kuhn AA, Herrington TM. Optimization and comparative evaluation of nonlinear deformation algorithms for atlas-based segmentation of DBS target nuclei. NeuroImage 2019; 184: 586-598.